Defense-to-Offense: PhRMA Readies to Protect Government Markets
This article was originally published in RPM Report
White House budget targeting biopharma with new cuts hits just as the Pharmaceutical Research & Manufacturers of America’s annual meeting gets under way.
You may also be interested in...
FDA recently featured an Alzheimer’s Disease clinical trial simulation tool as another positive, but low-visibility, step toward improving the drug development pathway for the disease. The process for accepting the tool may be as important as the tool itself.
NIH research support, intellectual property protections, and restoring the drug industry’s image moved up on the list of podium priorities at the PhRMA annual meeting in Washington, DC.
Jobs and governors go together like bread and butter. PhRMA is using the employment strength and new-economy mystique of biopharmaceuticals to try to line up strong advocates from the state houses in the upcoming fights over where to cut in health care spending.